{
  "id": "fda_guidance_chunk_0304",
  "title": "Introduction - Part 304",
  "text": "To document that the site is suitable for the trial (may be combined with 8.2.20) X 8.2.20 TRIAL INITIATION MONITORING REPORT To document that trial procedures were reviewed with the investigator and the investigator’s trial staff (may be combined with 8.2.19) X X Contains Nonbinding Recommendations 8.3 During the Clinical Conduct of the Trial In addition to having on file the above documents, the following should be added to the files during the trial as evidence that all new relevant information is documented as it becomes available. Title of Document Purpose Located in Files of Investigator/Institution Sponsor 8.3.1 INVESTIGATOR’S BROCHURE UPDATES To document that investigator is informed in a timely manner of relevant information as it becomes available X X 8.3.2 ANY REVISION TO: -Protocol/amendment(s) and CRF -Informed consent form -Any other written information provided to subjects -Advertisement for subject recruitment (if used) To document revisions of these trial related documents that take effect during trial X X 8.3.3 DATED, DOCUMENTED APPROVAL/FAVORABLE OPINION OF INSTITUTIONAL REVIEW BOARD IRB)/INDEPENDENT ETHICS COMMITTEE (IEC) OF THE FOLLOWING: 􀁸 Protocol amendment(s) 􀁸 Revision(s) of: 􀀐 Informed consent form 􀀐 Any other written information to be provided to the subject 􀀐 Advertisement for subject recruitment (if used) 􀁸 Any other documents given approval/favorable opinion 􀁸 Continuing review of trial (where required) To document that the amendment(s) and/or revision(s) have been subject to IRB/IEC review and were given approval/favorable opinion. To identify the version number and date of the document(s). X X Contains Nonbinding Recommendations 8.3.4 REGULATORY AUTHORITY(IES) AUTHORIZATIONS/APPROVALS/NOTIFICATIONS WHERE REQUIRED FOR: 􀁸 Protocol amendment(s) and other documents To document compliance with applicable regulatory requirements X (where required) X 8.3.5 CURRICULUM VITAE FOR NEW INVESTIGATOR(S) AND/OR SUBINVESTIGATOR(S) (See 8.2.10) X X 8.3.6 UPDATES TO NORMAL VALUE(S)/RANGE(S) FOR MEDICAL/LABORATORY/TECHNICAL PROCEDURE(S)/TEST(S) INCLUDED IN THE PROTOCOL To document normal values and ranges that are revised during the trial (see 8.2.11) X X 8.3.7 UPDATES OF MEDICAL/LABORATORY/TECHNICAL PROCEDURES/TESTS -Certification or -Accreditation or -Established quality control and/or external quality assessment or -Other validation (where required) To document that tests remain adequate throughout the trial period (see 8.2.12) X (where required) X 8.3.8 DOCUMENTATION OF INVESTIGATIONAL PRODUCT(S) AND TRIAL-RELATED MATERIALS SHIPMENT (See 8.2.15) X X 8.3.9 CERTIFICATE(S) OF ANALYSIS FOR NEW BATCHES OF INVESTIGATIONAL PRODUCTS (See 8.2.16) X 8.3.10 MONITORING VISIT REPORTS To document site visits",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 407232,
  "end_pos": 408768,
  "tokens": 512,
  "tags": [
    "design",
    "statistical",
    "regulatory",
    "clinical_trial",
    "consent",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.699Z"
}